Sarvodaya Hospital in Faridabad, Delhi NCR, has inaugurated its Theranostics and Nuclear Medicine Centre, introducing Terbium-161 PSMA therapy to treat patients with advanced metastatic castration-resistant or hormone-refractory prostate cancer. This development positions the hospital among the few in India offering such a precision-based treatment for late-stage prostate cancer.

Alongside this, the Sarvodaya Cancer Institute has launched CAR-T Cell therapy, expanding its capabilities to treat blood-related cancers such as leukaemia, lymphoma, and multiple myeloma. With these advanced therapies, the hospital now provides comprehensive cancer care—from diagnosis to cutting-edge treatment—all within a single facility.

Dr. Swagat Dash, Head of Department and Senior Consultant in Nuclear Medicine at the institute, emphasized the significance of this advancement in precision oncology. He affirmed the team’s commitment to offering innovative and high-quality cancer treatments.

Dr. Dinesh Pendharkar, Director of the Sarvodaya Cancer Institute, noted that the introduction of both Theranostics and CAR-T Cell therapy is redefining the concept of complete cancer care. He stressed that the hospital aims to revolutionize how complex cancers are treated in India by bringing together state-of-the-art therapies under one roof.

With this launch, Sarvodaya Hospital has established itself as a leader in delivering next-generation oncology care, catering to both solid tumors and blood cancers through a multidisciplinary and technologically advanced approach.